Advertisement


Stephanie Walker on Increasing the Participation of Black Women With Metastatic Breast Cancer in Clinical Trials

2022 ASCO Annual Meeting

Advertisement

Stephanie Walker, a former nurse and current activist with the Metastatic Breast Cancer Alliance, discusses findings from the BECOME project (Black Experience of Clinical Trials and Opportunities for Meaningful Engagement). They show that, even though Black patients comprise between 4% and 6% of all clinical trial participants, Black women with metastatic breast cancer are willing to consider taking part if steps were taken to increase their awareness, build trust through clear communication with health-care providers, involve people of shared racial/ethnic identity and health experience, and help patients find and access trials (Abstract 1014).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
My project for ASCO this year was to include or increase participation of black men and women with metastatic breast cancer in clinical trials. First of all, I think we need to inform. We not only need to inform the patients about clinical trials, but we also need to inform you as a healthcare provider to ask us. Because the majority of the patients that were asked on this survey, if they knew about clinical trials, they didn't know. I think it is part of the job of the healthcare provider to ask us. Don't assume that we don't know about it, or we know about it and choose not to. Don't assume that we can't afford it. Don't assume that we're not educated enough to do this. Everybody needs to be informed. Next, we need to inspire. You need to inspire us as the patient. You need to help build that bond regarding trust and the healthcare provider, which is you. We need to inspire trust, even though we know the trials and tribulations in the past, we need to go forward. You need to ensure that we know where we can get in touch with people regarding the clinical trials. We also need to ensure that we know how to utilize the resources, to look for clinical trials or where to find those. Also, you need to address the barriers. Financial is the biggest barrier that we have. You need to help us by providing a meal because a clinical trial is all day. Or parking. We have childcare that we need to attend to. Help address some of those little barriers. They may seem little to you, but they are huge barriers for us. If you take care of the barriers, ensure that we know where to contact or where to enroll in clinical trials, inspire, develop the trust, and we need to inform the patient and yourself about including and talking to us about clinical trials. With that being said, we are going to do a follow-up study to reach those that we were unable to reach, which were those people in rural communities that are not connected to internet or not connected to a university-based institution, because 80% of all the cancer patients are treated in community-based cancer centers. I encourage you to look at other methods of including us in clinical trials. Instead of having me fly from the east coast to the west coast, to do a clinical trial or fly from the east coast to the west coast, to get CT scans when I can get them five minutes down the road. I need you to address some of those logistics, some of the barriers regarding finances. I also need you to know us. Get to know your patients in that 15 minutes, I know is a short period of time that you have to spend with us in the office, but you also need to inform us. Do not assume. Inform us of clinical trials.

Related Videos

Bladder Cancer

Sumanta K. Pal, MD, on Urothelial Carcinoma: New Results on Cabozantinib Plus Atezolizumab

Sumanta K. Pal, MD, of City of Hope National Medical Center, discusses findings from the COSMIC-021 study, which showed that cabozantinib plus atezolizumab demonstrated encouraging clinical activity with manageable toxicity in patients with inoperable locally advanced or metastatic urothelial carcinoma. The combination was administered as first-line therapy in cisplatin-based chemotherapy–eligible and –ineligible patients and as second- or later-line treatment in those who received prior immune checkpoint inhibitors (Abstract 4504).

Skin Cancer

Georgina V. Long, MD, PhD, on Melanoma: New Data on Pembrolizumab, Dabrafenib, and Trametinib

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, The University of Sydney, discusses findings from the NeoTrio trial on neoadjuvant pembrolizumab alone, in sequence with, or concurrent with dabrafenib plus trametinib in patients with resectable BRAF-mutant stage III melanoma. The study may help clinicians determine the optimal combination of therapy (Abstract 9503).

Prostate Cancer

Alicia K. Morgans, MD, MPH, and Ian D. Davis, PhD, MBBS, on Prostate Cancer: Updated Overall Survival Outcomes With Enzalutamide

Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Ian D. Davis, PhD, MBBS, of Monash University and Eastern Health, discuss the latest findings from ANZUP Cancer Trials Group’s ENZAMET cooperative group trial of enzalutamide in patients with metastatic hormone-sensitive prostate cancer. The results corroborate the benefit of enzalutamide with improved overall survival, and involve some exploratory subgroup analyses (Abstract LBA5004).

Prostate Cancer

Alicia K. Morgans, MD, MPH, and Michael S. Hofman, MBBS, on Prostate Cancer: New Data on Lutetium-177–PSMA-617 (LuPSMA) vs Cabazitaxel

Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Michael S. Hofman, MBBS, of Peter MacCallum Cancer Centre, University of Melbourne, discuss follow-up results on LuPSMA vs cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel treatment. The findings suggest that LuPSMA is a suitable option for this population, with fewer adverse events, higher response rates, improved patient-reported outcomes, and similar overall survival compared with cabazitaxel (Abstract 5000).

Head and Neck Cancer

Sue S. Yom, MD, PhD, on Oropharyngeal Cancer and the Feasibility of a Cell-Free DNA Plasma Assay

Sue S. Yom, MD, PhD, of the University of California, San Francisco, discusses a translational analysis from the NRG-HN002 study. This phase II trial established the feasibility of the tumor tissue–modified viral (TTMV) human papillomavirus DNA assay in clinical trial specimens. The goal is to use such an assay to measure tumor volume, levels of TTMV over the course of treatment, and the association of TTMV to treatment outcomes (Abstract 6006).

 

Advertisement

Advertisement




Advertisement